Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

AI Briefing

• – Apogee Therapeutics' Zumilokibart shows 75% and 86% of patients maintaining EASI-75 and vIGA 0/1 at 52 weeks, respectively, with deepening response across lesional and itch endpoints.
• – Zumilokibart demonstrated durable maintenance of response in moderate-to-severe atopic dermatitis patients.
• – Deepening response observed across all lesional and itch endpoints with every 3- and 6-month dosing in the full population of patients initially randomized to zumilokibart.